eLearning

Patient Resources

Brands

Guidelines

Hypertension Management Across the Full Patient Spectrum

DPP4-inhibitors in T2DM: What does the EVIDENCE really say?

T2D Treatment Options

Understanding T2D Disease

CRM Story

Management of Hypertension Across the Full Patient Spectrum

The Ws and Hs of Empagliflozin in Clinical Practice

Back to Basics in Heart Failure

Optimising RAS blockade in diabetes and CKD

Expert perspectives in the management of High CV risk patients

Fundamentals of Mild-to-moderate Hypertension Management

DPP4-inhibitors in T2DM: What does the EVIDENCE really say?

East meets West: Practical Guidance for Optimizing Stroke Prevention in AF Patients and the Role of Dabigatran

Key Insight from ESC/EHRA Guideline for AF Management

Hypertension Management Across the Full Patient Spectrum

STEPS to Success: Simplicity and Safety

Secondary Prevention of Recurrent Stroke: A Case Study

Stroke Prevention in AF: Comorbidities

New Approach to T2DM: Do DPP4 inhibitors like linagliptin still fit in?

Hypertension control for all Pinoys: Managing HPN across its full spectrum

Not all DPP4i are the Same

Hypertension and Atrial Fibrillation: A Conundrum?

Role of Telmisartan in Hypertension in People with High CV Risk

Current Guidelines in the Management of Hypertension: Where do ARBs fit in?

Linagliptin: 10 Years of Simplicity

Heart Failure Quick Bites

Understanding the role of SGLT2i in the full spectrum of Heart Failure

Unmet needs in Hypertension Management: Safety and Efficacy of ARBs in Hypertensive Patients with Diabetes

HPN in CKD: Achieving Control Amidst the Pandemic?

A Decade of Simplicity in T2D Management: Why it Matters?

10 Years of Simplicity in Managing Type 2 Diabetes

Holistic Management of Hypertension with HF: Home Care and Addressing Occupational Challenges

A Decade of Simplicity Experience in T2DM: Why it Matters?

Hypertension and macrovascular risk: Minimising CV risk at home and at work

Offering Simplicity, Safety and Success in the Management of T2D

RAS Blockade in the Management of Hypertension in AF Recurrence Prevention

Meet the masters: Management of hypertension in patients with diabetes and CKD

Stroke Prevention: From Foresight to Second Chances

Managing Patients with AF & Intracranial Hemorrhage

Treatment Evolution: Practical Approach on SPAF Management

PSH Webisode Series: Hypertension and Heart Failure

PSH Webisode Series: Treatment in Hypertension in Patients with COPD

PSH Webisode Series: Preventing Atrial Fibrillation in Hypertensive Patients

PSH Webisode Series: Hypertension and Macrovascular Disease

PSH Webisode Series: Hypertension in CKD

Managing hypertension and diabetes: Addressing challenges at home and at work

10 Years of Simplicity in Managing Type 2 Diabetes

A decade of Simplicity Experience in T2D management: Why it matters?

COPD and Hypertension: What’s the Connection?

Empagliflozin (JARDIANCE) as a Heart Failure Therapy

Empagliflozin Heart Failure: EMPEROR-Reduced and Preserved Studies

ABCs of COPD - Respimat Device

ABCs of COPD - Why Choose LAMA/LABA

ABCs of COPD - Inhaled Steroids in COPD

ABCs of COPD - Inhaleability

Delivering 10 years of Improvements in Diabetes Care

HPN in CKD: Achieving Control Amidst the Pandemic?

Role of EGFR TKIs in uncommon and compound mutations

Multiplex screening to detect uncommon and compound EGFR mutations

Latest clinical research focus on the Targeted Therapy

The Discipline of Unified CRM Management in T2D: Improving Patients Outcomes through SGLT2i

The Future of T2D: A Holistic Approach in T2D Management with SGLT2i + DPP4i FDC

Latest Update of Targeted Therapy in Lung Cancer

Upfront EGFR TKIs Selection: 1st, 2nd, or 3rd Generation?

Breaking Down the Evidence: Empagliflozin’s Role in Improving Glucose Control and CV Outcomes in T2D Patients

The Future of T2D: A Holistic Approach in T2D Management with SGLT2i + DPP4i FDC

Optimizing HTN Management in a Changing World: 2020 ISH Guidelines & its Clinical Applications

10 Years of Simplicity in Managing Type 2 Diabetes

Towards the Cardio-Renal management of Heart Failure patients

EMPEROR Trial Program

A Match Made to Last: The Merits of a DPP4i + SGLT2i Combination in T2D Care

A Match Made to Last: The Merits of a DPP4i + SGLT2i Combination in T2D Care

10 Years of Simplicity in T2D Management

How to Succeed in the Long Game of T2D: Keeping the Management Simple

Breaking Down the Evidence: Empagliflozin's Role in Improving Glucose Control and CV Outcomes in T2D Patients

Moving the Treatment Landscape Forward in the Cardio-Renal-Metabolic Management of T2D

Introduction to PF-ILD

Introduction to SSc-ILD

Introduction to IPF

EMPEROR Preserved: Revolutionizing Heart Failure Management